Ipsen S.A. (LON:0MH6)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 11.61B +38.3% |
| Revenue (ttm) | 3.70B +14.1% |
| Net Income | 441.39M +14.4% |
| EPS | 5.31 +14.9% |
| Shares Out | n/a |
| PE Ratio | 26.29 |
| Forward PE | 11.26 |
| Dividend | 1.38 (0.96%) |
| Ex-Dividend Date | Jun 3, 2026 |
| Volume | 390 |
| Open | 168.20 |
| Previous Close | 168.60 |
| Day's Range | 164.00 - 168.50 |
| 52-Week Range | 109.00 - 176.60 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormo... [Read more]
Financial Performance
In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.
Financial numbers in EUR Financial StatementsNews
Ipsen Earnings Call Transcript: Q2 2026
H1 2026 saw robust sales and margin growth, driven by all therapeutic areas and supported by three positive phase III readouts and two strategic acquisitions. Upgraded guidance reflects strong momentum, with continued investment in R&D and commercial launches.
Ipsen Earnings release: Q2 2026
Ipsen released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Ipsen Slides: Q2 2026
Ipsen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Ipsen Quarterly report: Q2 2026
Ipsen has published its Q2 2026 quarterly earnings report on July 30, 2026.
Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
Bylvay missed the study's primary objective of showing an improvement in native liver survival rates compared to placebo.
Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree
The drugmaker sees gaps in its portfolio and has the financial means to fill them, its chief business officer said, signaling more deals are to come after this week's pair of acquisitions.
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million
The move marks Ipsen's second acquisition this week after its agreement to take over Kartos Therapeutics, a company developing a drug to treat a rare blood cancer.
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND , 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement...
French biotech company Ipsen to buy Kartos Therapeutics for $450 million
Ipsen will buy U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with a late-stage blood cancer treatment, the French biotech company said on Monday.
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen's oncology pipeline.
Ipsen S.A. – Evolution of the composition of the Board of Directors
Ipsen S.A. – Evolution of the composition of the Board of Directors PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Mrs. Karen Witts has resigned from her position ...
Annual General Meeting of Ipsen S.A. held on 13 May 2026
Annual General Meeting of Ipsen S.A. held on 13 May 2026 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announ...
Ipsen Earnings Call Transcript: Q1 2026
Q1 2026 saw 22.6% sales growth, driven by all therapeutic areas, with strong gains in rare disease and neuroscience. Guidance for 2026 is reaffirmed, but caution remains due to anticipated generic competition for Somatuline in H2.
Ipsen Earnings release: Q1 2026
Ipsen released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Ipsen Slides: Q1 2026
Ipsen has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Ipsen Earnings Call Transcript: H2 2025
Double-digit sales and profit growth were achieved, with strong performance across all therapeutic areas and a robust pipeline. 2026 guidance anticipates continued double-digit growth, limited generic competition for Somatuline, and significant R&D and business development milestones.
Ipsen Annual report: H2 2025
Ipsen has published its H2 2025 annual report on February 12, 2026.
Ipsen Earnings release: H2 2025
Ipsen released its H2 2025 earnings on February 12, 2026, summarizing the period's financial results.
Ipsen Slides: H2 2025
Ipsen has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 12, 2026.
Ipsen Earnings Call Transcript: Q3 2025
Double-digit sales and margin growth led to upgraded 2025 guidance, with rare disease and neuroscience segments driving strong performance. Pipeline advances include the ImCheck acquisition and positive IPN10200 data, while Somatuline faces gradual generic erosion in 2026.
Ipsen Earnings release: Q3 2025
Ipsen released its Q3 2025 earnings on October 22, 2025, summarizing the period's financial results.
Ipsen Slides: Q3 2025
Ipsen has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 22, 2025.
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) Attachment 2025 Half-year Financial Report_Ipsen SA
Ipsen Earnings Call Transcript: H1 2025
H1 2025 saw 11.4% sales growth, margin expansion, and strong cash flow, prompting upgraded full-year guidance. Pipeline advances and new approvals, especially in oncology and rare disease, support continued growth, while Somatuline faces generic headwinds.